Safety and efficacy of low-dose Dasatinib (50 mg) in patients with newly-diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Trial Profile

Safety and efficacy of low-dose Dasatinib (50 mg) in patients with newly-diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 New trial record
    • 06 Jun 2017 Early results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top